Sucampo Pharma (SCMP) Tops Q1 EPS by 2c

Sucampo Pharma (NASDAQ: SCMP) reported Q1 EPS of $0.21, $0.02 better than the analyst estimate of $0.19. Revenue for the quarter came in at $47.2 million versus the consensus estimate of $44.11 million.

GUIDANCE:

Sucampo Pharma sees FY2016 EPS of $0.97-$1.07, versus the consensus of $1.05. Sucampo Pharma sees FY2016 revenue of $195-205 million, versus the consensus of $202.3 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15